Bill 118 hr 8999, also known as the Dialysis-Related Amyloidosis Treatment Act of 2024, aims to address the issue of dialysis-related amyloidosis (DRA) by providing funding for research, treatment, and education related to this condition. DRA is a rare but serious complication that can occur in patients undergoing long-term dialysis treatment for kidney failure.
The bill proposes to allocate funds to support research into the causes and potential treatments for DRA, as well as to improve access to specialized care for patients affected by this condition. Additionally, the bill includes provisions for increasing public awareness and education about DRA, in order to help prevent its occurrence and improve outcomes for those who develop the condition.
Overall, the Dialysis-Related Amyloidosis Treatment Act of 2024 seeks to address an important and often overlooked issue in the healthcare system, and to improve the quality of care for patients undergoing dialysis treatment. It represents a bipartisan effort to support research, treatment, and education related to DRA, with the ultimate goal of improving outcomes for patients affected by this condition.